Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06853886 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation

Study acronym: LiNKeB2
StatusRecruiting
PhaseNot applicable
Started2025-08-12
View on ClinicalTrials.gov ↗

Amendment history

2026-05-19
Study Status, Contacts/Locations v2
Study sitesdetails revised at 1 of 3 sites
2025-09-15
Not Yet Recruiting→Recruiting Study Status, Oversight, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2028-07-01→2028-10-01
Completion date2028-07-01→2028-10-01
Start dateestimated 2025-04-01→confirmed 2025-08-12
Study sitesdetails revised at 3 of 3 sites
2025-02-25
Original filing
Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow us to understand the molecular signature of NK and B cells in the context of HBV infection.
Trial Details
NCT Number NCT06853886
Lead Sponsor University Hospital, Limoges
Collaborators: National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Conditions Chronic Hepatitis B Virus
Enrollment 140 participants
Start Date 2025-08-12
Primary Completion 2028-10-01 (estimated)
Study Completion 2028-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-20